for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Alterity Therapeutics Ltd (ADR)

ATHE.OQ

Latest Trade

0.87USD

Change

-0.07(-6.99%)

Volume

40,352

Today's Range

0.85

 - 

0.92

52 Week Range

0.85

 - 

2.75

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
0.93
Open
0.92
Volume
40,352
3M AVG Volume
10.06
Today's High
0.92
Today's Low
0.85
52 Week High
2.75
52 Week Low
0.85
Shares Out (MIL)
2,030.95
Market Cap (MIL)
42.86
Forward P/E
-171.74
Dividend (Yield %)
--

Next Event

Q2 2022 Alterity Therapeutics Ltd Earnings Release

Latest Developments

More

Alterity Therapeutics Gets Positive Guidance For ATH434 Phase 2 Clinical Trial

Dr David Stamler Appointed CEO

Alterity Therapeutics Says David Stamler Appointed CEO

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Alterity Therapeutics Ltd (ADR)

Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company focuses on developing disease modifying treatments for neurodegenerative conditions. The Company's lead product candidate, ATH434, is being used for the treatment of various Parkinson's disease, Dementia with lewy bodies (DLB) as well as various forms of atypical Parkinsonism, such as Multiple System Atrophy (MSA). ATH434, is a set of molecules designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. The Company also has a drug discovery platform generating chemical to intercede in disease processes.

Industry

Business Services

Contact Info

L 3 460 Bourke St

MELBOURNE, VIC

3000

Australia

+61.3.93494906

https://alteritytherapeutics.com/

Executive Leadership

Geoffrey Paul Kempler

Non-Executive Chairman of the Board

David A. Stamler

Chief Executive Officer

Kathryn J. E. Andrews

Chief Financial Officer

Phillip D. Hains

Company Secretary

Tristan Edwards

Non-Executive Director

Key Stats

2.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2022(E)

0.0K
EPS (USD)

2021

-0.007

2022(E)

-0.006
Price To Earnings (TTM)
--
Price To Sales (TTM)
2,918.87
Price To Book (MRQ)
1.57
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.22
LT Debt To Equity (MRQ)
0.12
Return on Investment (TTM)
-81.19
Return on Equity (TTM)
-70.40

Latest News

Latest News

BRIEF-Alterity Therapeutics Qualifies For Temporary Relief From Nasdaq On Minimum Bid Price Requirement

* QUALIFIES FOR TEMPORARY RELIEF FROM NASDAQ REGARDING MINIMUM BID PRICE REQUIREMENT Source text for Eikon: Further company coverage:

BRIEF-Alterity Receives Non-Compliance Notice Regarding Nasdaq Minimum Bid Price Requirement

* ALTERITY RECEIVES NON-COMPLIANCE NOTICE REGARDING NASDAQ MINIMUM BID PRICE REQUIREMENT Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up